Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors - Wikidata - awgldk - TriplyDB

Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors

Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors

http://www.wikidata.org/entity/Q24674107

about

Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade Does dopexamine influence regional vascular tone and oxygenation during intestinal hypotension?Cardiac inotropes inhibit the oedema caused by nifedipine in rabbit skin Failure of dopexamine to maintain haemodynamic improvement in patients with chronic heart failure Haemodynamic response to dopexamine hydrochloride in postinfarction heart failure: lack of tolerance after continuous infusion Blood concentrations of dopexamine in patients during and after orthotopic liver transplantation The haemodynamic and myocardial effects of dopexamine: a new beta 2-adrenoceptor and dopaminergic agonist.Catecholamines in critical care. The commonly used catecholamines: receptor and clinical profile, indications and dosages.FPL 63012AR: a potent D1-receptor agonist.Use of inotropes and vasopressor agents in critically ill patients.Some aspects of heart beta adrenoceptor function.Reducing the risk of major elective surgery: randomised controlled trial of preoperative optimisation of oxygen delivery.Therapeutic applications of drugs acting on peripheral dopamine receptors.Dopexamine: studies in the general intensive care unit and after liver transplantation.Dopexamine in congestive heart failure: how do the pharmacological activities translate into the clinical situation?The effects of dopexamine on the cardiovascular system of the dog Cardiovascular actions of dopexamine in anaesthetized and conscious dogs.Inhibition of Uptake1 by dopexamine hydrochloride in vitro.Effects of chronic intravenous infusions of dopexamine and isoprenaline to rats on D1-, beta 1- and beta 2-receptor-mediated responses.The effects of dopexamine, a new dopamine analogue, on platelet function in stress.Impairment of renal function after cardiopulmonary bypass is not influenced by dopexamine.Effects of dopexamine on acute necrotising pancreatitis in rats.Haemodynamic effects of dopexamine on postprandial splanchnic hyperaemia.Circulatory and diuretic effects of dopexamine infusion in low-birth-weight infants with respiratory failure.Influence of dopexamine hydrochloride on haemodynamics and regulators of circulation in patients undergoing major abdominal surgery.Effects of dopamine, dopexamine and dobutamine on renal excretory function during experimental sepsis in conscious rats.Effect of dopexamine hydrochloride on sympathetic neuroeffector transmission in rabbit isolated pulmonary artery.A comparison of dopexamine and dopamine to prevent renal impairment in patients undergoing orthotopic liver transplantation.Enhancing liver blood flow after cardiopulmonary bypass: the effects of dopamine and dopexamine.Do human cardiac beta-2 adrenoceptors play a (patho)physiological role in regulation of heart rate and/or contractility?The Management of Sepsis: A Practical Review

P2860

Q24680142-8E703162-A2B8-4D23-AC03-BB65DE443A3B Q30868797-ACE14150-477D-4AE8-A939-493F1D792AE3 Q32175908-D4032895-AC17-4413-A4F0-7076778DB5D5 Q33999599-2C964388-76E1-4FC4-B621-C992C245BB57 Q34016827-87298A2C-31B3-40C5-A3A3-CD8AEB65DC2B Q34346001-50405F58-0A1C-4B40-8732-3ACC7B4ECBE4 Q34447352-DCC16DB9-ED75-4E33-8707-5F9B696047FB Q35530734-0E906D07-CD59-4C5C-91BC-EF2C4F197517 Q35887846-A02EBFF2-2033-42F3-B301-6F9FDE2AADCF Q36147248-CAF64D2A-6381-4A51-A2FC-35DFD04CD748 Q36416038-E62F0856-DDC0-44A9-8B2B-D63E520013B0 Q37441506-8E297B4B-6F6A-4C0D-8F90-BC62DD7F829C Q37598885-078F00D3-599A-4371-95F6-59F3BA8A8CBE Q37803611-DEC7B022-C121-4075-A396-997B5DEE87C8 Q38367074-65DBEE30-C734-4668-B468-210CBB85109C Q41787117-B3677F5B-89FD-4935-AC0A-2961FEE82FE3 Q41923460-FFA4C38C-CE47-47CC-8632-11EE9C8A7B80 Q42159838-7433501B-BF83-4F19-80DA-DF7F0A8D4026 Q42700627-4D3009C2-26EA-47D2-864E-62DAC5780289 Q43204742-92645BA4-C39B-4B37-80BC-37CBD98503E4 Q43647657-83A5E083-244B-45D0-8A78-F31EC6CBBBC9 Q43844846-ADDDDC7C-2A12-41FE-B582-32FD51558083 Q44845875-AAD211D1-A9C2-45B1-A2AA-7B32FBE12E70 Q47340017-978DF55B-DCEE-4B91-A683-AC1614ED333E Q51497684-B896B125-7F43-491C-8FCF-1E39D2ED38C1 Q51546949-6F2E9E67-7E43-481F-8082-263521D1F82B Q51575745-E97884AA-376B-4D29-A4BD-1CD39ABED1A6 Q51708855-3B2B2307-7116-47C9-B6A7-2A7A25326C7C Q52866014-B70090BE-0359-49EF-9C63-CBC123C0E09C Q54117674-D07A2B37-A29E-4AFC-8F63-09A90C37D6D7 Q57527492-D9AE33F3-836F-4622-8346-CE4C0D075E3F

P2860

Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors

http://www.wikidata.org/entity/Q24674107

description

1985 nî lūn-bûn

@nan

1985 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

1985 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

1985年の論文

@ja

1985年論文

@yue

1985年論文

@zh-hant

1985年論文

@zh-hk

1985年論文

@zh-mo

1985年論文

@zh-tw

1985年论文

@wuu

name

Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors

@ast

Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors

@en

Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors

@nl

type

label

Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors

@ast

Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors

@en

Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors

@nl

prefLabel

Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors

@ast

Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors

@en

Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors

@nl

P1433

Q24674107-578C8686-8F0F-49B5-BE50-2FC2334E5907

P1476

Q24674107-EAD918AA-49CD-40D8-8BCC-3771EF12C03F

P2093

Q24674107-37F59D80-06B4-4E23-929A-9CAB415CC9B4

Q24674107-5FAED7A7-CE51-47AB-8A7E-63F646F3FD83

Q24674107-8CEBE6B4-6AA7-493D-B841-DD9BCE578696

Q24674107-8DE43F35-1A49-4E8D-B92D-04705C299CFD

Q24674107-94FF336F-5E16-4FFE-BE66-E4B33DA87508

Q24674107-9E3B60E0-883F-4EB1-A9E8-EF17A4A01510

Q24674107-A210586B-71DC-4C00-B844-11D08DB0E529

Q24674107-A36F81C3-4AC4-419C-906B-CD27F34CDB56

Q24674107-B755B8D3-571B-4C74-8974-8FF0400022A2

P2860

Q24674107-01A1E702-6AB7-4FB0-AC63-91ABDB8F9F55

Q24674107-03741F9E-DC25-4DAD-94E3-C64020BCC19E

Q24674107-0B1B182D-5BC2-4522-B676-179C3B252913

Q24674107-10F951C2-5E13-40F4-9A3D-9CE93CEDFB36

Q24674107-14300507-603C-4F48-A5E2-CF7E8A6492A5

Q24674107-2B28BE0E-DBCB-480F-9434-B8BA0BAE5FB6

Q24674107-3C6558B0-3F08-4A15-B2A5-EE729614C3C8

Q24674107-5F9D4C05-AE08-433A-9C2B-9721B6D16AD9

Q24674107-77A01C88-BA64-4D58-B188-AF14CF6C21B9

Q24674107-83B979FD-6993-48C4-BBAD-E5D3676D2C72

P304

Q24674107-6671BA5C-5973-43CE-A39F-C7E66B54686B

P31

Q24674107-32C46243-5964-44AA-8284-23AA1FF9F149

P356

Q24674107-7F082292-3B68-43CE-83C1-28EEDDB6A7CC

P407

Q24674107-89610CEC-76E3-4EAA-89FD-6F3D42A2D889

P433

Q24674107-954338A0-B31A-4C1F-A336-CAFFBF843C98

P478

Q24674107-E432EDA5-6DE9-46E7-A3BB-710F2752E2C7

P577

Q24674107-E9BC786F-3BF1-4568-BECE-C3366A718985

P5875

Q24674107-11FEDDFB-EF97-48CF-8A7B-173E1B3D1559

P698

Q24674107-E245BF3C-F5A9-47D8-AF9A-AC4AAFD50F78

P921

Q24674107-b20e3d96-2511-407f-bee4-a8fd3cbdd1f3

P932

Q24674107-DFAEA90F-97B7-4E10-B434-D422CF170C7B

P356

J.1476-5381.1985.TB10554.X

P1433

British Journal of Pharmacology

P1476

Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors

@en

P2093

F Ince

http://www.w3.org/2001/XMLSchema#string

G W Smith

http://www.w3.org/2001/XMLSchema#string

J B Farmer

http://www.w3.org/2001/XMLSchema#string

J C Hall

http://www.w3.org/2001/XMLSchema#string

J Dixon

http://www.w3.org/2001/XMLSchema#string

R A Brown

http://www.w3.org/2001/XMLSchema#string

R G Humphries

http://www.w3.org/2001/XMLSchema#string

S E O'Connor

http://www.w3.org/2001/XMLSchema#string

W T Simpson

http://www.w3.org/2001/XMLSchema#string

P2860

Dobutamine: development of a new catecholamine to selectively increase cardiac contractility

EFFECT OF DOPAMINE IN MAN: AUGMENTATION OF SODIUM EXCRETION, GLOMERULAR FILTRATION RATE, AND RENAL PLASMA FLOW

Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine.

Modulation of noradrenergic transmission in the rabbit ear artery by dopamine

Analysis of histamine receptors in the central thermoregulatory mechanism of Mastomys natalensis.

Vasodilator therapy of cardiac failure (second of two parts).

Cardiovascular and renal actions of dopamine: potential clinical applications.

Cardiovascular dopamine receptors: physiological, pharmacological and therapeutic implications.

The effects of dopexamine on the cardiovascular system of the dog

Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist.

P304

599-608

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1476-5381.1985.TB10554.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P577

1985-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

20293201

http://www.w3.org/2001/XMLSchema#string

P698

2862944

http://www.w3.org/2001/XMLSchema#string

P921

P932

1916510

http://www.w3.org/2001/XMLSchema#string